GPS / USDC

GPS / USDT

GPS / BNB

GPS / FDUSD

MUBARAK / USDT

DAI / JPY

MUBARAK / USDC

SYS / USDT

USDT / BRL

MKR / USDC

PENGU / TRY

PENGU / USDT

PENGU / USDC

PENGU / FDUSD

DEXE / USDT

ARPA / BTC

PYTH / FDUSD

W / USDC

ALPHA / USDT

SYRUP / USDT

NIFTY50 DIV POINT

CAPITAL TRUST LTD

MAYASHEEL VENTURES LTD

PRIME FOCUS LIMITED

SAFE ENTER RETAIL FIX LTD

NET AVENUE TECHNOLOGIES L

ALMONDZ GLOBAL SEC LTD

NDR AUTO COMPONENTS LTD

HIMADRI SPECIALITY CHEM L

LLOYDS ENTERPRISES LTD

MEDICO REMEDIES LIMITED

SUPREME HOLDIN N HOSP I L

GACM TECHNOLOGIES LIMITED

KCK INDUSTRIES LTD

CONFIDENCE PETRO IND LTD.

NARMADA AGROBASE LIMITED

DIGITIDE SOLUTIONS LTD

TD POWER SYSTEMS LTD.

RAJGOR CASTOR DERIVATI L

DYNAMIC CABLES LIMITED

Click here to get full coverage on SYRUS Study Explores AZD0486 Safety, Dosing in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD - AJMC

SYRUS Study Explores AZD0486 Safety, Dosing in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD  AJMC

SYRUS Study Explores AZD0486 Safety, Dosing in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD - AJMC

Click here to get full coverage on Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial - Nature

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial  Nature

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial - Nature

Click here to get full coverage on Durable Responses Are Achievable for Steroid-Refractory Chronic GVHD - Targeted Oncology

Durable Responses Are Achievable for Steroid-Refractory Chronic GVHD  Targeted Oncology

Durable Responses Are Achievable for Steroid-Refractory Chronic GVHD - Targeted Oncology

Click here to get full coverage on Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma - OncLive

Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma  OncLive

Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma - OncLive

Click here to get full coverage on Monjuvi Approved for Relapsed/Refractory Follicular Lymphoma - Hematology Advisor

Monjuvi Approved for Relapsed/Refractory Follicular Lymphoma  Hematology Advisor

Monjuvi Approved for Relapsed/Refractory Follicular Lymphoma - Hematology Advisor

Click here to get full coverage on CAR-T Therapy Shows Durable Responses in Relapsed/Refractory LBCL - Oncology Nurse Advisor

CAR-T Therapy Shows Durable Responses in Relapsed/Refractory LBCL  Oncology Nurse Advisor

CAR-T Therapy Shows Durable Responses in Relapsed/Refractory LBCL - Oncology Nurse Advisor

Click here to get full coverage on Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma - Roche

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma  Roche

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma - Roche

Click here to get full coverage on FDA approves Monjuvi for relapsed, refractory follicular lymphoma - Medical Xpress

FDA approves Monjuvi for relapsed, refractory follicular lymphoma  Medical Xpress

FDA approves Monjuvi for relapsed, refractory follicular lymphoma - Medical Xpress

Click here to get full coverage on RHI Magnesita and BPI, Inc. Announce Strategic Joint Venture to Accelerate Circular Economy Initiatives in North America - Business Wire

RHI Magnesita and BPI, Inc. Announce Strategic Joint Venture to Accelerate Circular Economy Initiatives in North America  Business Wire

RHI Magnesita and BPI, Inc. Announce Strategic Joint Venture to Accelerate Circular Economy Initiatives in North America - Business Wire

Click here to get full coverage on Rogue Immune Cells: The Hidden Culprit Behind Refractory Celiac Disease - Celiac.com

Rogue Immune Cells: The Hidden Culprit Behind Refractory Celiac Disease  Celiac.com

Rogue Immune Cells: The Hidden Culprit Behind Refractory Celiac Disease - Celiac.com

Click here to get full coverage on Refractory Ranula Following Surgery for Tongue Cancer: A Case Report - Cureus

Refractory Ranula Following Surgery for Tongue Cancer: A Case Report  Cureus

Refractory Ranula Following Surgery for Tongue Cancer: A Case Report - Cureus

Click here to get full coverage on Unexplained or Refractory Chronic Cough in Adults - The New England Journal of Medicine

Unexplained or Refractory Chronic Cough in Adults  The New England Journal of Medicine

Unexplained or Refractory Chronic Cough in Adults - The New England Journal of Medicine

Click here to get full coverage on FDA Fast Track: Schrödinger's SGR-1505 Targets Resistant Blood Cancer with Promising Phase 1 Data - Stock Titan

FDA Fast Track: Schrödinger's SGR-1505 Targets Resistant Blood Cancer with Promising Phase 1 Data  Stock Titan

FDA Fast Track: Schrödinger's SGR-1505 Targets Resistant Blood Cancer with Promising Phase 1 Data - Stock Titan

Click here to get full coverage on Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients - ScienceDirect.com

Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients  ScienceDirect.com

Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients - ScienceDirect.com

Click here to get full coverage on Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL - Targeted Oncology

Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL  Targeted Oncology

Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL - Targeted Oncology

Click here to get full coverage on Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium - Nature

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium  Nature

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium - Nature

Click here to get full coverage on CARTITUDE-1 Trial Shows Unprecedented 5-Year Remission in Relapsed/Refractory Multiple Myeloma: Sundar Jagganath, MBBS - AJMC

CARTITUDE-1 Trial Shows Unprecedented 5-Year Remission in Relapsed/Refractory Multiple Myeloma: Sundar Jagganath, MBBS  AJMC

CARTITUDE-1 Trial Shows Unprecedented 5-Year Remission in Relapsed/Refractory Multiple Myeloma: Sundar Jagganath, MBBS - AJMC

Click here to get full coverage on Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL - OncLive

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL  OncLive

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL - OncLive

Click here to get full coverage on Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 - Nature

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3  Nature

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 - Nature

Click here to get full coverage on Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial - Nature

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial  Nature

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial - Nature

Click here to get full coverage on Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey - Nature

Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey  Nature

Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey - Nature

Click here to get full coverage on STAR Locally Prolongs Effective Refractory Period and Increases Ventricular Tachycardia Cycle Length Without Short-Term Scar Formation or Functional Decline: Insights From a Translational Porcine Model Study - American Heart Association Journals

STAR Locally Prolongs Effective Refractory Period and Increases Ventricular Tachycardia Cycle Length Without Short-Term Scar Formation or Functional Decline: Insights From a Translational Porcine Model Study  American Heart Association Journals

STAR Locally Prolongs Effective Refractory Period and Increases Ventricular Tachycardia Cycle Length Without Short-Term Scar Formation or Functional Decline: Insights From a Translational Porcine Model Study - American Heart Association Journals

Click here to get full coverage on Oncolytic virus VG161 in refractory hepatocellular carcinoma - Nature

Oncolytic virus VG161 in refractory hepatocellular carcinoma  Nature

Oncolytic virus VG161 in refractory hepatocellular carcinoma - Nature

Click here to get full coverage on Current Treatment Approaches for Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Pharmacy Times

Current Treatment Approaches for Relapsed/Refractory Diffuse Large B-Cell Lymphoma  Pharmacy Times

Current Treatment Approaches for Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Pharmacy Times

Click here to get full coverage on Efficacy of vacuum erectile device in refractory erectile dysfunction: a systematic review and meta-analysis - Nature

Efficacy of vacuum erectile device in refractory erectile dysfunction: a systematic review and meta-analysis  Nature

Efficacy of vacuum erectile device in refractory erectile dysfunction: a systematic review and meta-analysis - Nature

Click here to get full coverage on Refractory Angina - www.heart.org

Refractory Angina - www.heart.org

Click here to get full coverage on Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus | Cell Research - Nature

Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus | Cell Research  Nature

Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus | Cell Research - Nature

Click here to get full coverage on Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes | Blood Cancer Journal - Nature

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes | Blood Cancer Journal  Nature

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes | Blood Cancer Journal - Nature

Click here to get full coverage on Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission - ScienceDirect.com

Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission  ScienceDirect.com

Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission - ScienceDirect.com

Click here to get full coverage on Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma - BioSpace

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma  BioSpace

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma - BioSpace

Click here to get full coverage on Evaluating refractory material performance in pyrometallurgical recycling of lithium-ion batteries under a reducing atmosphere - ScienceDirect.com

Evaluating refractory material performance in pyrometallurgical recycling of lithium-ion batteries under a reducing atmosphere  ScienceDirect.com

Evaluating refractory material performance in pyrometallurgical recycling of lithium-ion batteries under a reducing atmosphere - ScienceDirect.com

Click here to get full coverage on Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series - ScienceDirect.com

Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series  ScienceDirect.com

Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series - ScienceDirect.com

Click here to get full coverage on High-throughput design of a light and strong refractory eutectic medium entropy alloy with outstanding He-ion irradiation resistance - Science | AAAS

High-throughput design of a light and strong refractory eutectic medium entropy alloy with outstanding He-ion irradiation resistance  Science | AAAS

High-throughput design of a light and strong refractory eutectic medium entropy alloy with outstanding He-ion irradiation resistance - Science | AAAS

Click here to get full coverage on Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma - The New England Journal of Medicine

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma  The New England Journal of Medicine

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma - The New England Journal of Medicine

Click here to get full coverage on Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma  OncLive

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Click here to get full coverage on Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study - The Lancet

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study  The Lancet

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study - The Lancet

Click here to get full coverage on Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis - Nature

Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis  Nature

Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis - Nature

Click here to get full coverage on Two-shot optimization of compositionally complex refractory alloys - ScienceDirect.com

Two-shot optimization of compositionally complex refractory alloys  ScienceDirect.com

Two-shot optimization of compositionally complex refractory alloys - ScienceDirect.com

Click here to get full coverage on Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest - The Lancet

Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest  The Lancet

Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest - The Lancet

Click here to get full coverage on Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial - The Lancet

Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial  The Lancet

Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial - The Lancet

Click here to get full coverage on Serum Biomarkers for Refractory Active Rheumatoid Arthritis Remain Elusive - AJMC

Serum Biomarkers for Refractory Active Rheumatoid Arthritis Remain Elusive  AJMC

Serum Biomarkers for Refractory Active Rheumatoid Arthritis Remain Elusive - AJMC

Click here to get full coverage on Anomalous component-dependent lattice thermal conductivity in MoWTaTiZr refractory high-entropy alloys - ScienceDirect.com

Anomalous component-dependent lattice thermal conductivity in MoWTaTiZr refractory high-entropy alloys  ScienceDirect.com

Anomalous component-dependent lattice thermal conductivity in MoWTaTiZr refractory high-entropy alloys - ScienceDirect.com

Click here to get full coverage on Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma - The New England Journal of Medicine

Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma  The New England Journal of Medicine

Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma - The New England Journal of Medicine

Click here to get full coverage on Data-driven design of novel lightweight refractory high-entropy alloys with superb hardness and corrosion resistance - Nature

Data-driven design of novel lightweight refractory high-entropy alloys with superb hardness and corrosion resistance  Nature

Data-driven design of novel lightweight refractory high-entropy alloys with superb hardness and corrosion resistance - Nature

Click here to get full coverage on Laser-based additive manufacturing of refractory metals and their alloys: A review - ScienceDirect.com

Laser-based additive manufacturing of refractory metals and their alloys: A review  ScienceDirect.com

Laser-based additive manufacturing of refractory metals and their alloys: A review - ScienceDirect.com

Click here to get full coverage on Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study - ASCO Publications

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study  ASCO Publications

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study - ASCO Publications

Click here to get full coverage on Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax | Leukemia - Nature

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax | Leukemia  Nature

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax | Leukemia - Nature

Click here to get full coverage on Ductilization of single-phase refractory high-entropy alloys via activation of edge dislocation - ScienceDirect.com

Ductilization of single-phase refractory high-entropy alloys via activation of edge dislocation  ScienceDirect.com

Ductilization of single-phase refractory high-entropy alloys via activation of edge dislocation - ScienceDirect.com

Click here to get full coverage on The efficacy of penoscrotal decompression for refractory ischaemic priapism: a systematic review and meta-analysis - Nature

The efficacy of penoscrotal decompression for refractory ischaemic priapism: a systematic review and meta-analysis  Nature

The efficacy of penoscrotal decompression for refractory ischaemic priapism: a systematic review and meta-analysis - Nature

Click here to get full coverage on Redifferentiation of Radioiodine-Refractory Thyroid Cancer following Genotype-Guided MAPK/BRAF Inhibition - Journal of Nuclear Medicine

Redifferentiation of Radioiodine-Refractory Thyroid Cancer following Genotype-Guided MAPK/BRAF Inhibition  Journal of Nuclear Medicine

Redifferentiation of Radioiodine-Refractory Thyroid Cancer following Genotype-Guided MAPK/BRAF Inhibition - Journal of Nuclear Medicine

Click here to get full coverage on Design of BCC/FCC dual-solid solution refractory high-entropy alloys through CALPHAD, machine learning and experimental methods - Nature

Design of BCC/FCC dual-solid solution refractory high-entropy alloys through CALPHAD, machine learning and experimental methods  Nature

Design of BCC/FCC dual-solid solution refractory high-entropy alloys through CALPHAD, machine learning and experimental methods - Nature

Click here to get full coverage on Designing ductile refractory high-entropy alloys - Nature

Designing ductile refractory high-entropy alloys  Nature

Designing ductile refractory high-entropy alloys - Nature

Click here to get full coverage on Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT) - Nature

Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT)  Nature

Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT) - Nature

Click here to get full coverage on Placebo responses in clinical trials of refractory chronic cough: mechanisms, challenges, and mitigation strategies - The Lancet

Placebo responses in clinical trials of refractory chronic cough: mechanisms, challenges, and mitigation strategies  The Lancet

REFRACTORY

Price Chart

Key Statistics

Technicals

About REFRACTORY

Latest News

SYRUS Study Explores AZD0486 Safety, Dosing in Relapsed/Refractory B-Cell ALL: Ibrahim Aldoss, MD - AJMC

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial - Nature

Durable Responses Are Achievable for Steroid-Refractory Chronic GVHD - Targeted Oncology

Advanced Charts

Top Gainers

Top Losers